Strong Insider Buying Found in the Underlying Holdings of BTAL

The AGF U.S. Market Neutral Anti-Beta Fund (BTAL) shows 54.0% of its weighted underlying holdings have experienced insider buying within the past six months, signaling potential executive confidence. Notably, DENTSPLY SIRONA Inc (XRAY), a 32.37% weighted holding, and AGCO Corp. (AGCO), representing 30.53% of the ETF's assets, both saw multiple directors and officers making significant share purchases. This concentrated insider activity in major portfolio components suggests internal optimism regarding their future prospects.

Analysis

The AGF U.S. Market Neutral Anti-Beta Fund (BTAL) shows a strong positive signal from insider activity, with 54.0% of its weighted underlying holdings having experienced insider buying within the last six months. This activity is highly concentrated in two key holdings which together represent over 62% of the fund's reported assets. DENTSPLY SIRONA Inc (XRAY), a 32.37% weighted holding, saw its President & CEO purchase 11,306 shares at $17.72 and a director make two significant purchases. Concurrently, AGCO Corp. (AGCO), representing 30.53% of the fund's assets, recorded multiple Form 4 filings from two separate directors indicating share purchases, with one director buying on three separate occasions in August and November. The fact that multiple high-level insiders at these two core companies are actively increasing their positions suggests a strong, sustained belief from within that their respective stocks are undervalued or poised for positive performance.

Key Decisions for Investors

• Given that over 62% of the fund's reported assets are in stocks with recent, significant insider buying, investors in BTAL should view this as a strong confirmation of the fund's underlying stock-picking thesis.